Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Contribution of prison-based hepatitis C treatment initiations to overall treatment uptake in Victoria, Australia.
Griffin S, Lee Wilkinson A, Winter R, Hajarizadeh B, MacIsaac M, Papaluca T, Holmes J, Lloyd AR, Carson J, Craigie A, Hellard M, Stoové M, Thompson A. Griffin S, et al. Lancet Reg Health West Pac. 2024 Jul 5;48:101139. doi: 10.1016/j.lanwpc.2024.101139. eCollection 2024 Jul. Lancet Reg Health West Pac. 2024. PMID: 39045483 Free PMC article. No abstract available.
Unsuccessful Direct Acting Antiviral Hepatitis C Treatment Among People With HIV: Findings From an International Cohort.
Harney BL, Sacks-Davis R, van Santen DK, Stewart AC, Matthews GV, Carson JM, Klein MB, Lacombe K, Wittkop L, Salmon D, Leleux O, Merchadou L, van der Valk M, Smit C, Prins M, Boyd A, Berenguer J, Jarrin I, Rauch A, Hellard ME, Doyle JS. Harney BL, et al. Among authors: carson jm. Liver Int. 2025 Jan;45(1):1-13. doi: 10.1111/liv.16203. Liver Int. 2025. PMID: 39656170 Free PMC article.
Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV.
Hosseini-Hooshyar S, Martinello M, Yee J, Read P, Baker D, Post JJ, Finlayson R, Bloch M, Doyle JS, Shaw D, Hellard M, Petoumenos K, Carson J, Dore GJ, Matthews GV; CEASE study team. Hosseini-Hooshyar S, et al. AIDS. 2020 Jul 15;34(9):1347-1358. doi: 10.1097/QAD.0000000000002562. AIDS. 2020. PMID: 32590433
Reinfection incidence and risk among people treated for recent hepatitis C virus infection.
Martinello M, Carson JM, Van Der Valk M, Rockstroh JK, Ingiliz P, Hellard M, Nelson M, Lutz T, Bhagani S, Kim AY, Hull M, Cordes C, Moon J, Feld JJ, Gane E, Rauch A, Bruneau J, Tu E, Applegate T, Grebely J, Dore GJ, Matthews GV; React Study Group. Martinello M, et al. Among authors: carson jm. AIDS. 2023 Oct 1;37(12):1883-1890. doi: 10.1097/QAD.0000000000003651. Epub 2023 Jul 17. AIDS. 2023. PMID: 37467042 Free PMC article.
Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010-19: an analysis of data from a consortium of prospective cohort studies.
Sacks-Davis R, van Santen DK, Boyd A, Young J, Stewart A, Doyle JS, Rauch A, Mugglin C, Klein M, van der Valk M, Smit C, Jarrin I, Berenguer J, Lacombe K, Requena MB, Wittkop L, Leleux O, Bonnet F, Salmon D, Matthews GV, Guy R, Martin NK, Spelman T, Prins M, Stoove M, Hellard M; InCHEHC Collaboration. Sacks-Davis R, et al. Lancet HIV. 2024 Feb;11(2):e106-e116. doi: 10.1016/S2352-3018(23)00267-9. Epub 2024 Jan 12. Lancet HIV. 2024. PMID: 38224708
Cohort Profile: International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC).
van Santen DK, Stewart A, Doyle JS, Stoové MA, Asselin J, Klein MB, Young J, Berenguer J, Jarrin I, Lacombe K, Wittkop L, Leleux O, Salmon D, Bonnet F, Rauch A, Mugglin C, Matthews G, Prins M, Smit C, Boyd A, van der Valk M, Sacks-Davis R, Hellard ME; InCHEHC Study Group. van Santen DK, et al. Int J Epidemiol. 2024 Feb 1;53(1):dyad154. doi: 10.1093/ije/dyad154. Int J Epidemiol. 2024. PMID: 38066671 Free PMC article. No abstract available.
48 results